Fimecs
Fujisawa
About Fimecs
FIMECS is a protein degradation technology-based drug discovery biotech focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The human body is comprised of at least 18,097 proteins.It has been revealed that 1,500 of them are related to certain diseases, nevertheless only about 300 proteins have been regarded as druggable targets by small molecule drug discovery and all the rest have been undruggable.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $7.6M
- Funding stage: M&A
- Last round: Series A (May 2020)
- Website: fimecs.com
- Phone: +81 0466-96-0261
Industries & Categories
Biotechnology, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/fimecs-91231 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.